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Abstract
Background: Ao-dake-humi is a traditional Japanese bamboo foot stimulator consisting of a half-pipe-shaped step
made of bamboo used to stimulate the foot by stepping on it, and is commonly used to promote general health
among the elderly in Japan. However, its efficacy has not been reported in the scientific literature. This study was
performed to investigate the role of ao-dake-humi focusing on lower urinary tract symptoms (LUTS), constipation,
and hypersensitivity to cold (HC).
Methods: Participants with LUTS, constipation, or HC were enrolled in this study. Ao-dake-humi was used twice a
day for 28 days. Before and 28 days after starting ao-dake-humi use, international prostate symptom score (IPSS),
quality-of-life (QoL) score, and overactive bladder symptom score (OABSS) were measured to evaluate the efficacy
of ao-dake-humi on LUTS. To evaluate the objective efficacy of ao-dake-humi on LUTS, a frequency-volume chart
(FVC) was plotted in LUTS patients for 3 days. A visual analogue scale (VAS) was used to evaluate the efficacy of
ao-dake-humi on constipation (VAS-constipation) and HC (VAS-HC) in the participants with constipation or HC.
Results: A total of 24 participants were enrolled in this study. Twenty-one participants had LUTS, 11 had
constipation, and 17 participants had HC. IPSS, especially storage-subscore, QoL score and OABSS, decreased
significantly after use of ao-dake-humi. The use of ao-dake-humi increased maximal bladder capacity, resulting in
a significant decrease in urinary frequency as determined from the FVC. In accordance with the results of VAS-
constipation and VAS-HC, both constipation and HC were significantly relieved after ao-dake-humi use.
Conclusion: The results of this prospective pilot study indicated that ao-dake-humi is safe and has therapeutic
efficacy in cases of LUTS, constipation and HC. The possibility of using ao-dake-humi as physical neuromodulation
therapy was shown in the management of LUTS, constipation and HC.
Trial registration: UMIN000019333 (UMIN-CTR, Registered October-15-2015) retrospectively registered.
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Background
Lower urinary tract symptoms (LUTS) and constipation
are common problems, especially among the elderly [1].
On the other hand, skin sensation, especially to cold
temperature, can be related to urinary bladder function.
This symptomatic phenomenon is called “Hie-Shou” in
Kampo-medicine (Japanese traditional medicine). Hie-
Shou can be translated as hypersensitivity to cold (HC)
[2]. HC induces several secondary symptoms, such as
urinary urgency [2, 3]. Previously, we reported the im-
portance of simultaneous management of LUTS, consti-
pation and HC considering interaction among pelvic
organs and skin [2] (Fig. 1a). On the other hand, foot
massage and reflexology, are candidates for management
of LUTS, constipation and HC [4–7]. The theory behind
reflexology is that specific areas of foot match and are
connected to specific organs of the body as shown in
Fig. 1b. In Japan, a traditional bamboo foot stimulator
called ao-dake-humi is commonly used to promote gen-
eral health, and can be applied for management of
LUTS, constipation, and HC as shown in Fig. 1a, b.
However, the exact role of ao-dake-humi has not been
proven. Therefore, we attempted to evaluate the safety
and therapeutic efficacy of ao-dake-humi on LUTS,
constipation and HC in this prospective pilot study.
Methods
This study was conducted between July 2013 and October
2015. The trial registration number is UMIN000019333
(UMIN-CTR, registration date is 15th Oct. 2015).
Eligible participants were >20 y.o. with LUTS, consti-
pation and/or HC. LUTS patients with IPSS >13 or
dissatisfied with current LUTS treatments were enrolled.
Constipation and HC were evaluated according to self-
description. Exclusion criteria were as follows: patients
who could not make the decision themselves, those with
a custom of receiving foot massage, those incapable of
walking by themselves, and those with a history of recur-
rent urinary tract infection or bladder stones. All of the
LUTS patients had already received some medical care
in a hospital or a private clinic. In the process of the pre-
vious management of LUTS before enrolling this trial,
urinary tract infection and cancer including prostate
cancer had already excluded. Subjects were also ex-
cluded if they received surgery, diagnosed malignant
disease, and used other medical interventions, such as
drugs, within the previous 3 months. Participants could
continue to take medication for LUTS and constipation
to maintain the same condition before and after the
study. However, the participants were not permitted to
start or stop any intervention for LUTS, constipation or
HC during the study.
Ao-dake-humi used in this study was made of bamboo,
40 cm in length, 8.5 cm in width, 4.5 cm in height, and
almost 290 g in weight. The ao-dake-humi was brought
to each participant’s home, and used twice a day, in the
morning (after waking up) and evening (after taking a
bath/shower or before going to bed) for 28 days. Holding
something such as the wall, desk, or pillar, participants
placed the arches of both feet on the ao-dake-humi,
and then made repeated steps for 2 min in a set as
shown in Fig. 2. Figure 2 includes the photographs
with one of the author (T.M.). In accordance with
the usual use of ao-dake-humi, steps were made 30–
60 times/min, and participants could control the rate
by themselves. If participants felt pain, they could
reduce use to once a day. The rate of ao-dake-humi
use was noted using a diary to evaluate the exact
a b
Fig. 1 a Relationship among urinary bladder, bowel, and skin sensation. Interactions of pelvic organs and skin sensation on pathological
condition are briefly presented. Ao-dake-humi can be a therapeutic stimulator for management via simultaneous and indirect effect on lower
urinary tract symptoms, constipation, and hypersensitivity to cold. This figure is modified schema shown in Ref #2. b A brief foot chart in
reflexology. Only main and large areas are shown in this figure, and small parts are excluded for ease of understanding. Each area of the foot
matches specific body parts, and is connected to promoting health of each part of the body by massage. The colon and urinary bladder are
located in the arch area, which is the “hot spot” stimulated by ao-dake-humi
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intervention and harmfulness of ao-dake-humi. All
of the participants recorded ao-dake-humi use as
“done” or “none” in the diary. Total practical rate
(= number of sets performed/(2 sets × 28 days)) was
calculated in all of the participants. Moreover, ad-
verse events were also evaluated in all of the partici-
pants during this research.
Before and 28 days after ao-dake-humi, international
prostate symptom score (IPSS), quality-of-life (QoL)
score, and overactive bladder symptom score (OABSS)
were measured for evaluation of efficacy of ao-dake-
humi on LUTS. IPSS storage, voiding, and postvoiding
subscores were also assessed [8, 9]. Visual analogue scale
(VAS) was used to evaluate the efficacy of ao-dake-humi
on constipation (VAS-constipation) and HC (VAS-HC) in
the enrolled participants with constipation or HC. VAS for
constipation and HC were originally made, and were used
to evaluate constipation and HC like pain scale. The line is
10 cm in length on the paper. The left edge of line is zero,
and the right edge is maximal as 10 points. Zero means that
patients have not any symptoms. And, 10 points means that
patients have severe symptoms which patients can imagine
maximally. Patients can place a vertical mark on the line to
describe the severity of their symptoms intuitively. If the
patients have severe symptoms, patients can put on the
right part of the line. The length from zero to the point on
which patients described the symptoms is treated as sever-
ity of symptoms, and the decrease or increase of length are
considered as improvement or worsening of symptoms.
IPSS, QoL score, OABSS, VAS-constipation, and VAS-HC
was presented in Table 1 (written in English).
To evaluate the objective efficacy of ao-dake-humi on
LUTS, a frequency-volume chart (FVC) was used. The
FVC on 3 continuous days was recorded in all of the
enrolled LUTS participants before and 28 days after
starting ao-dake-humi use. The average total voided
volume, daytime voided volume, nighttime voided vol-
ume, total urinary frequency in a day, daytime urinary
frequency, and nighttime urinary frequency were evalu-
ated for each day. The average mean voided volume,
maximal voided volume, and minimal voided volume
were also evaluated. Nighttime micturition was defined
as micturition between 10:00 pm and 6:00 am.
All data are presented as the means ± SEM. The data
were analysed using Excel-based statistical program file,
Excel TouKei (Social Survey Research Information Co.,
Ltd., Tokyo, Japan), and p < 0.05 was considered to
indicate significance. The changes before and after ao-
dake-humi were analysed using the paired t test.
Results and discussion
A total of 24 participants were enrolled in this study,
and their characteristics are shown in Table 2. The
results of subjective evaluation are shown in Table 3.
The baseline of total IPSS, QoL score, and OABSS
among LUTS patients is 14.7 ± 8.2, 4.3 ± 1.3, and 5.4 ±
3.6, respectively. Total IPSS, OABSS, and QoL score
were improved after ao-dake-humi use in the partici-
pants with LUTS. In analysis of IPSS subscores, storage
and postvoiding symptom subscores were significantly
improved after ao-dake-humi use. As the first step to
show the efficacy of ao-dake-humi on constipation and
Fig. 2 a Photo of ao-dake-humi. b, c, d Use of ao-dake-humi. b, c, d, e Holding something such as a wall, desk, or pillar, participants place both
feet on ao-dake-humi, and then make repeated steps for 2 min in a set
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Table 1 Medical interview sheet to evalutate lower urinary symptoms (LUTS) and visual analogue scale (VAS) to evaluate constipation and
hypersensitivity to cold (HC). International prostate symptom score (IPSS), quality of life (QoL) score, and overactive bladder symptom score
(OABSS) were used for LUTS. VAS were originally made to evaluate constipation and HC. Zero means that patients have not any symptoms.
And, 10 points means that patients have severe symptoms which patients can imagine maximally
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HC, evaluation was performed in this study using only
VAS-constipation and VAS-HC. In accordance with the
results, of the 11 participants with constipation, subject-
ive VAS-constipation score was improved in −31.8%
after ao-dake-humi use with statistical significance. Of
the 17 participants with HC, subjective score was signifi-
cantly improved in −21.9% of VAS-HC after ao-dake-
humi use. The results of objective evaluation are shown
in Table 4. Total urine volume did not change before
and 28 days after starting ao-dake-humi use. Total and
daytime urinary frequencies were decreased after ao-
dake-humi use. These results may have been due to an
increase in voided volume. Only the maximal voided
volume increased significantly after ao-dake-humi use;
mean and minimal voided volumes were also not signifi-
cantly increased.
Previous reports indicated that a decrease in envi-
ronmental temperature induces numerous physiological
responses, including increased urinary frequency in both
humans and animals [10, 11]. Previously, we reported
the relationship between HC and LUTS, and the efficacy
of simultaneous approaches using Kampo-medicine [2].
In this study, 60% of the enrolled participants had both
LUTS and HC, and the efficacy of ao-dake-humi on HC
was revealed subjectively. Moreover, constipation was
also improved after ao-dake-humi use. Five of 11 partici-
pants with constipation had received drug treatment
before starting this research. These results indicated that
ao-dake-humi is a candidate therapeutic option to
manage LUTS, constipation and HC. However, HC and
constipation were evaluated on the basis of self-description
using VAS. A further RCT with larger number of partici-
pants is needed.
Ao-dake-humi is a Japanese traditional home health
appliance based on the theory of reflexology, and can be
used at home to promote general health in daily use. Ao-





Age (y.o.) 65.2 ± 16.3
Body mass index (kg/m 2) 21.8 ± 2.2







LUTS and constipation 2
LUTS and HC 7
Constipation and HC 2
LUTS, constipation, and HC 7
Past history




Alpha 1-adrenocepter antagonist 8
Anticholinergic drug 1
Beta 3-adrenoceptor agonist 3
Cathartic drug 5
Characteristics of the enrolled patients in this study
LUTS lower urinary tract symptoms, HC hypersensitivity to cold
Table 3 Differences in lower urinary tract symptoms, constipation and hypersensitivity to cold (HC) before and after ao-dake-humi use
LUTS LUTS (N = 21) p value
IPSS Total −3.8 0.0002**
Voiding subscore −1.0 0.0592
Storage subscore −2.1 0.0000**
Postvoiding subscore −0.7 0.0060**
QOL score −1.2 0.0000**
OABSS −1.1 0.0070**
Constipation Constipation (N = 11)
VAS-constipation −31.8 0.0073**
HC HC (N = 17)
VAS-HC −21.9 0.0158*
LUTS lower urinary tract symptoms, IPSS international prostate symptom score, QOL quality of life, OABSS overactive bladder symptom score, HC hypersensitivity
to cold, VAS Visual analogue scale
Subjective effect of ao-dake-humi on lower urinary tract and constipation and hypersensitivity to cold. Different before and after ao-dakehumi was shown.
*: p < 0.05, ** p < 0.01
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dake-humi consists of a half-pipe-shaped foot-step made
of bamboo cut into pieces 30–40 cm in length, and is
widely used in Japan. The mechanisms of ao-dake-humi
promoting general health are not yet known. However,
neuromodulation and acupuncture may have similar
mechanisms of action on LUTS, constipation and HC.
Therefore, the effect of ao-dake-humi is thought not to
be due to exercise but to stimulation of afferent nerves
in the foot to modulate visceral organs, such as the urin-
ary bladder and colon. Indeed, some neuromodulation
equipment has been reported for treatment of LUTS,
constipation and faecal incontinence [12]. Electrical
stimulation [13–18], magnetic stimulation [19–22] and
interferential therapy [23, 24] are mainly used for modu-
lation via the sacral nerve or tibial nerve. Although the
precise mechanisms of neuromodulation are not yet
known, activation of afferent nerves may lead to activa-
tion of efferent nerves in the pelvic organs, including the
urinary bladder and colon [13, 14]. Physical stimulation,
such as acupuncture, reflexology or foot massage, can be
used as a source of neuromodulation via activation of
sensory afferent pathways. In addition, the theory of re-
flexology, including acupuncture, can also be adapted for
ao-dake-humi, and our hypothesis about ao-dake-humi
is described on Fig. 1a also. In reflexology, areas of the
foot are believed to correspond to the organs or struc-
tures of the body [25]. Acupuncture was reported to
have be effective for LUTS and constipation [26–30].
Moreover, in accordance with the foot chart of oriental
foot massage, the urinary bladder and colon are located
in the “hot spot” of ao-dake-humi stimulation (Fig. 1b).
Of course, the exercise effect of ao-dake-humi cannot
be completely excluded in this study. Therefore, an
RCT should be done between step-work-exercise versus
ao-dake-humi.
Ao-dake-humi has many advantages, such as its inex-
pensiveness, portability, and less risk of harm, compared
to other interventions, including electrical neuromodula-
tion. Ao-dake-humi costs about 5 dollars, and requires
little maintenance. Moreover, as ao-dake-humi can be
shared, it can be used in public spaces, such as hospitals
and nursing homes. Ao-dake-humi is lightweight (almost
300 g), and is therefore easily portable, and ideal for
daily use at home. Even in comparison with other similar
treatments, including acupuncture and massage, ao-
dake-humi has advantages. For example, the amount of
stimulation can be controlled procedure-dependently in
normal foot massage. In contrast, the amount of stimu-
lation of ao-dake-humi is controlled according to body-
weight and of each patient. The average body mass
index of the participants was 21.8 kg/m2, and obese par-
ticipants were not included in this study. Although ad-
equate methods should be proposed for participants
with obesity in future studies, ao-dake-humi can stand-
ardise the amount of stimulation for patients. Adverse
events associated with neuromodulation, such as infec-
tion, bleeding, pain, etc., have been reported [31, 32]. In
this study, only three participants complained of slight
pain due to ao-dake-humi use, and 98.5% of participants
achieved use of ao-dake-humi according to a review of
their diaries. All of the participants wished to continue
ao-dake-humi use after this study. Even the participants
that complained of slight pain at commencement of this
study eventually felt comfortable with ao-dake-humi
stimulation. There were no severe adverse events, such
as diarrhea or urinary retention, among the participants.
Of course, on theoretical grounds, it is impossible for
the participants to have any severe advised events
associated with use of ao-dake-humi. Compared with
other neuromodulators, this is the unquestionable ad-
vantage of ao-dake-humi in management of LUTS
and constipation.
However, this study had some limitations. In this pilot
study, 2 sets/day of 2 min of ao-dake-humi were done
for 28 days. There have been no reports regarding
adequate use of ao-dake-humi. Time, duration, and
frequency should be evaluated in future studies. The
most important limitation of this study is bias because
of its single-arm nature. Subjective results, such as IPSS
and OABSS, should be interpreted carefully. However,
Table 4 Objective values before and after ao-dake-humi based on frequency-volume-chart (FVC)
Before After p value
LUTS (N = 20)
Total urine volume (ml/day) 1684.7 ± 788.5 1669.1 ± 691.2 0.4543
Mean voided volume (ml) 169.7 ± 52.8 187.0 ± 67.0 0.0538
Maximal voided volume (ml) 331.5 ± 140.3 373.0 ± 139.0 0.0424*
Minimal voided volume (ml) 58.3 ± 31.4 72.8 ± 50.2 0.0948
Total urinary frequency (/day) 10.9 ± 3.5 9.8 ± 2.7 0.0065**
Day-time urinary frequency (/6–22 o’clock) 8.9 ± 2.7 7.9 ± 1.7 0.0162*
Night-time urinary frequency (/22–6 o’clock) 2.0 ± 1.7 1.8 ± 1.6 0.1898
Objective results of ao-dake-humi on LUTS. One of 21 patients did not make ao-dake-humi-diary
LUTS: lower urinary tract symptoms. *: p < 0.05, ** p < 0.01
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objective results from FVC indicated that ao-dake-humi
has efficacy for LUTS. Of course, objective evaluation
should be performed even for constipation and HC, and
more objective evaluation for LUTS, including uroflow-
metry, residual urine volume, and cystometry, should
also be performed in future studies. Lack of objective
evaluation of constipation and HC is also a limitation of
this study. However, object evaluation for constipation
without any intervention is difficult, and object measure-
ment of HC has not been established yet. Further investiga-
tion is needed to evaluate the exact role of ao-dake-humi
on constipation and HC. However, even with these limita-
tions, ao-dake-humi showed statistically relevant subjective
and objective results in this study, and there were no
adverse events. Thus, ao-dake-humi is a candidate of thera-
peutic option for LUTS, constipation and HC.
Conclusions
The results of this pilot study indicated that ao-dake-
humi improved subjective symptoms of LUTS, constipa-
tion and HC. Ao-dake-humi also increased maximal
voided volume leading to a reduction in urinary fre-
quency without any severe adverse events.
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